Ocrelizumab
Brand name: Ocrevus
Rank #389 of 500 drugs by total cost
$24.2M
Total Cost
639
Total Claims
$24.2M
Total Cost
26
Prescribers
$38K
Cost per Claim
247
Beneficiaries
3,047
30-Day Fills
$932K
Avg Cost/Provider
25
Avg Claims/Provider
About Ocrelizumab
Ocrelizumab (sold as Ocrevus) was prescribed 639 times by 26 Medicare Part D providers in 2023, costing the program $24.2M. At $38K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 386 | Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro) | $24.4M | 1,173,249 |
| 387 | Pegfilgrastim (Neulasta) | $24.4M | 3,096 |
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
| 389 | Ocrelizumab (Ocrevus) | $24.2M | 639 |
| 390 | Fenofibrate (Fenofibrate) | $24.2M | 670,936 |
| 391 | Empaglifloz/Linaglip/Metformin (Trijardy Xr) | $23.9M | 28,001 |
| 392 | Fluticasone Furoate (Arnuity Ellipta) | $23.7M | 74,825 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology